BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 12093321)

  • 1. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients.
    Fillet AM
    Drugs Aging; 2002; 19(5):343-54. PubMed ID: 12093321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis against herpesvirus infections in transplant recipients.
    Ljungman P
    Drugs; 2001; 61(2):187-96. PubMed ID: 11270937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral prophylaxis in organ transplant patients.
    Slifkin M; Doron S; Snydman DR
    Drugs; 2004; 64(24):2763-92. PubMed ID: 15563248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral skin infections in the elderly: diagnosis and management.
    Bansal R; Tutrone WD; Weinberg JM
    Drugs Aging; 2002; 19(7):503-14. PubMed ID: 12182687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.
    Wagstaff AJ; Faulds D; Goa KL
    Drugs; 1994 Jan; 47(1):153-205. PubMed ID: 7510619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and therapy of herpesvirus infections].
    Abb J
    Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):107-20. PubMed ID: 2986378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.
    Beyar-Katz O; Bitterman R; Zuckerman T; Ofran Y; Yahav D; Paul M
    Clin Microbiol Infect; 2020 Feb; 26(2):189-198. PubMed ID: 31536817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiherpesvirus agents. Their targets and therapeutic potential.
    Alrabiah FA; Sacks SL
    Drugs; 1996 Jul; 52(1):17-32. PubMed ID: 8799682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.
    Snoeck R; Andrei G; De Clercq E
    Drugs; 1999 Feb; 57(2):187-206. PubMed ID: 10188760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
    Tan HH; Goh CL
    Am J Clin Dermatol; 2006; 7(1):13-29. PubMed ID: 16489840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiviral prophylaxis].
    Graubner UB
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A69-76. PubMed ID: 11577365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in herpesvirus therapy.
    Naesens L; De Clercq E
    Herpes; 2001 Mar; 8(1):12-6. PubMed ID: 11867011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
    Wutzler P
    Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Wagstaff AJ
    Drugs; 1995 Aug; 50(2):396-415. PubMed ID: 8521764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Wagstaff AJ; Bryson HM
    Drugs; 1994 Aug; 48(2):199-226. PubMed ID: 7527325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valaciclovir: development, clinical utility and potential.
    Patel R
    Expert Opin Investig Drugs; 1997 Feb; 6(2):173-89. PubMed ID: 15989601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.